CDKN2A and familial pancreatic carcinoma: In pancreatic cancer cells, several genetic alterations are considered to be the basis for pancreatic cancer progression and its dismal prognosis; these alterations include oncogenic KRAS mutations, which occur in over 90% of cases, and inactivating mutations in suppressor genes such as TP53, SMAD4, and CDKN2A [14].